vasopressin · Baxter Hlthcare Corp · NDA 217569, 217766
Vasopressin In Sodium Chloride 0.9%
Earliest generic entry, as listed · earliest of 4 marketed strengths
27 Sep 2044
2 of 4 marketed strengths have no unexpired patent or exclusivity listed.
Blocked by patent: US 12447190.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12447190 | drug product · sets the listed date | 27 Sep 2044 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217569 · 001 · RLD | solution, intravenous | 20UNITS/100ML (0.2UNITS/ML) | 27 Sep 2044 |
| 217569 · 002 · RLD | solution, intravenous | 40UNITS/100ML (0.4UNITS/ML) | 27 Sep 2044 |
| 217766 · 001 · RLD | solution, intravenous | 20UNITS/100ML (0.2UNITS/ML) | open |
| 217766 · 002 · RLD | solution, intravenous | 40UNITS/100ML (0.4UNITS/ML) | open |
| 217766 · 003 · RLD · discontinued | solution, intravenous | 50UNITS/50ML (1UNIT/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |